Tomasz Stefaniak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tomasz Stefaniak has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Damian Palus
Department of Hypertension and Diabetology, Faculty of Medicine, Medical University of Gdańsk, 17 Mariana Smoluchowskiego Street, 80-214 Gdańsk, Poland
4 shared publications - Krzysztof Kuziemski
Department of Pulmonology, School of Public Health, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 78 Jagiellońska Street, 10-357 Olsztyn, Poland
4 shared publications - Martyna Ewa Gołębiewska
Faculty of Medicine, Department of Psychiatry, Medical University of Gdansk, Gdansk, Poland
3 shared publications - Olga Piątek-Dalewska
Department of Obstetrics and Gynecology, Medical University of Gdansk, Smoluchowskiego 17, 80-210 Gdansk, Poland
3 shared publications - Alan Majeranowski
Department of Cell Biology and Immunology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Dębinki 1 Street, 80-211 Gdańsk, Poland
2 shared publications - Krzysztof Grudziński
Faculty of Computer Science and New Technologies, WSB Merito University in Gdańsk, 238A Grunwaldzka Avenue, 80-266 Gdańsk, Poland
2 shared publications
Latest Publications
- Open Access
In-Hospital Complications Associated with Mortality in Patients Hospitalized for COVID-19: A Prospective Single-Center Cohort Study
Background and Objectives: We assessed associations of variables recorded within 24 h of admission and in-hospital complications with mortality in adults hospitalized for COVID-19. Materials and Methods: This prospective single-center cohort included 249 adults hospitalized in 2021. Four mortality classifiers underwent repeated cross-validation and 0.632+ bootstrap validation, a resampling method that combines apparent and out-of-bag performance while adjusting for overfitting. Separate logistic regressions evaluated mortality and acute kidney injury (AKI), with AKI specifications including or excluding baseline renal laboratory predictors. Results: In-hospital mortality was 22.5%. The 0.632+ bootstrap estimates of the area under the receiver operating characteristic curve were 0.862 for random forest, 0.769 for ridge logistic regression, 0.757 for linear discriminant analysis, and 0.552 for quadratic discriminant analysis. Higher lymphocyte count was associated with lower odds of death (odds ratio 0.237; 95% confidence interval 0.089–0.632). AKI, shock, and renal replacement therapy were associated with high conditional mortality. Conclusions: Admission-assessment variables provided exploratory prognostic information on in-hospital mortality in adults hospitalized for COVID-19. Sparse events, incomplete covariate information, and the single-center setting limit inference. Independent validation, calibration, and assessment of clinical benefit are required before implementation.
Open AccessIn-Hospital Complications Associated with Mortality in Patients Hospitalized for COVID-19: A Prospective Single-Center Cohort Study
Background and Objectives: We assessed associations of variables recorded within 24 h of admission and in-hospital complications with mortality in adults hospitalized for COVID-19. Materials and Methods: This prospective single-center cohort included 249 adults hospitalized in 2021. Four mortality classifiers underwent repeated cross-validation and 0.632+ bootstrap validation, a resampling method that combines apparent and out-of-bag performance while adjusting for overfitting. Separate logistic regressions evaluated mortality and acute kidney injury (AKI), with AKI specifications including or excluding baseline renal laboratory predictors. Results: In-hospital mortality was 22.5%. The 0.632+ bootstrap estimates of the area under the receiver operating characteristic curve were 0.862 for random forest, 0.769 for ridge logistic regression, 0.757 for linear discriminant analysis, and 0.552 for quadratic discriminant analysis. Higher lymphocyte count was associated with lower odds of death (odds ratio 0.237; 95% confidence interval 0.089–0.632). AKI, shock, and renal replacement therapy were associated with high conditional mortality. Conclusions: Admission-assessment variables provided exploratory prognostic information on in-hospital mortality in adults hospitalized for COVID-19. Sparse events, incomplete covariate information, and the single-center setting limit inference. Independent validation, calibration, and assessment of clinical benefit are required before implementation.
- 1 July 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-6
Mobile PRISM App - Feasibility Study
- 1 July 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-6
Mobile PRISM App - Feasibility Study
- Open Access
- 12 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Prognosis of patients with a history of organ transplantation during active COVID-19 infection
Solid organ transplant recipients were among the most vulnerable groups during the COVID-19 pandemic. Chronic immunosuppression and multiple comorbidities
- 12 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessPrognosis of patients with a history of organ transplantation during active COVID-19 infection
Solid organ transplant recipients were among the most vulnerable groups during the COVID-19 pandemic. Chronic immunosuppression and multiple comorbidities
- Open Access
- 25 February 2025
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 32 (2) , 120-129
Association of pre-existing comorbidities and complications with inpatient COVID-19 mortality — a single-center retrospective study
Background: This study evaluates the impact of pre-existing comorbidities and in-hospital complications on COVID-19 mortality rates. Methods: A retrospective single-center study was conducted using electronic health records from 640 COVID-19 patients hospitalized at the University Clinical Centre in Gdansk, Poland, between November 2020 and May 2021. Patients were categorized based on disease severity into stable or ICU wards based on the disease severity. Data on demographics, comorbidities, complications, and treatments were collected and verified. Statistical analyses, including odds ratios (ORs) and confidence intervals (CIs), assessed mortality risk factors supported by python-based processing. Results: The mean patient age was 67 years (SD ± 15.89), comprising 39% females (n = 250) and 60.94% males (n = 390). Mortality risk was highest in patients aged 65 years and older (OR 3.00; 95% CI, 1.97–4.60). Among the pre-existing comorbidities, chronic kidney disease (OR 3.28; 95% CI, 2.12–5.09), atrial fibrillation (OR 2.43; CI 95%, 1.63–3.61), and heart failure (OR 2.89; 95% CI, 1.91–4.37) were significant predictors of mortality. In hospital complications, such as severe respiratory failure requiring ICU ventilation (OR 23.59; 95% CI, 2.81–197.87), myocardial infarction (OR 25.43; 95% CI, 3.16–204.97), acute kidney injury requiring renal replacement therapy (OR 19.15; 95% CI, 6.49–56.51), sepsis (OR 7.22, 95% CI, 3.77–13.84), stroke, further increased mortality risk. Conclusions: COVID-19 patients with pre-existing renal and cardiovascular conditions face a higher risk of fatal outcomes. Early diagnosis and intervention targeting these complications are vital to in reducing mortality. Further research is needed to reconcile disparities with existing literature. Keywords: COVID-19 complications SARS-CoV-2 comorbidity in-hospital mortality risk factors
- 25 February 2025
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 32 (2) , 120-129
Open AccessAssociation of pre-existing comorbidities and complications with inpatient COVID-19 mortality — a single-center retrospective study
Background: This study evaluates the impact of pre-existing comorbidities and in-hospital complications on COVID-19 mortality rates. Methods: A retrospective single-center study was conducted using electronic health records from 640 COVID-19 patients hospitalized at the University Clinical Centre in Gdansk, Poland, between November 2020 and May 2021. Patients were categorized based on disease severity into stable or ICU wards based on the disease severity. Data on demographics, comorbidities, complications, and treatments were collected and verified. Statistical analyses, including odds ratios (ORs) and confidence intervals (CIs), assessed mortality risk factors supported by python-based processing. Results: The mean patient age was 67 years (SD ± 15.89), comprising 39% females (n = 250) and 60.94% males (n = 390). Mortality risk was highest in patients aged 65 years and older (OR 3.00; 95% CI, 1.97–4.60). Among the pre-existing comorbidities, chronic kidney disease (OR 3.28; 95% CI, 2.12–5.09), atrial fibrillation (OR 2.43; CI 95%, 1.63–3.61), and heart failure (OR 2.89; 95% CI, 1.91–4.37) were significant predictors of mortality. In hospital complications, such as severe respiratory failure requiring ICU ventilation (OR 23.59; 95% CI, 2.81–197.87), myocardial infarction (OR 25.43; 95% CI, 3.16–204.97), acute kidney injury requiring renal replacement therapy (OR 19.15; 95% CI, 6.49–56.51), sepsis (OR 7.22, 95% CI, 3.77–13.84), stroke, further increased mortality risk. Conclusions: COVID-19 patients with pre-existing renal and cardiovascular conditions face a higher risk of fatal outcomes. Early diagnosis and intervention targeting these complications are vital to in reducing mortality. Further research is needed to reconcile disparities with existing literature. Keywords: COVID-19 complications SARS-CoV-2 comorbidity in-hospital mortality risk factors
- Open Access
- 27 November 2024
- Published by Juniper Publishers
- Vol. 16 (02) , 001-004
Current Evidence on the Surgical Treatment of Pancreatic Cancer Related Pain-A Mini-Review
TPP’s are seen following blunt traumatic injuries to thorax most commonly in settings of road traffic accidents. Usually pleuro-parenchymal abnormalities like pneumo-hemothorax, contusions, hematomas, lacerations are expected with blunt traumatic thoracic injuries along with rib fractures and flail chest.
- 27 November 2024
- Published by Juniper Publishers
- Vol. 16 (02) , 001-004
Open AccessCurrent Evidence on the Surgical Treatment of Pancreatic Cancer Related Pain-A Mini-Review
TPP’s are seen following blunt traumatic injuries to thorax most commonly in settings of road traffic accidents. Usually pleuro-parenchymal abnormalities like pneumo-hemothorax, contusions, hematomas, lacerations are expected with blunt traumatic thoracic injuries along with rib fractures and flail chest.
- Open Access
Analysing COVID treatment outcomes in dedicated wards at a large university hospital in northern Poland. A result-based observational study
Introduction: Presenting outcomes of patients hospitalised for coronavirus disease (COVID-19) should be put in context and comparison with other facilities. Number of statistical parameters can be used to compare effectiveness of treatment, however varied methodology applied in studies can impede or hinder a reliable comparison. The aim of this study is to present outcomes of COVID-19 treatment in our facility using simplest parameters allowing for intercenter comparison - case fatality ratio (CFR), length of stay (LOS) and transparent patients’ characteristics, and to discuss factors affecting mortality in COVID-19. Methods: The data were collected from patients hospitalized in COVID-19 general and ICU isolation wards in the University Clinical Centre (UCC) in Gdansk, Poland, from November 2020 to June 2021, using a computer-based patient record system. The group consisted of 642 patients – 144 (39,1 %) were women and 391 (60,9 %) were men, with a median age of 69 (IQR 59-78) years. Values of LOS and CFR were calculated and analysed. Results: Overall CFR for the analysed period was 24,8 %, varying from 19,9 % in January to May 2021 to 33,8 % in November to December 2020. CFR was 18,9 % in general ward and 70,7 % in ICU. All ICU patients required intubation and mechanical ventilation, and forty-four (75,9 %) of them developed acute respiratory distress syndrome (ARDS). Average length of stay was 13,1 (± 7,1) days. Conclusion: CFR in the general ward in UCC was analogous to published outcomes, but higher in our ICU ward. It resulted from more rigorous ICU admittance criteria in UCC compared to other facilities, which corresponds with patients’ severe clinical condition and unfavourable prognosis. Heterogeneity of methods assessing initial clinical condition in different facilities makes a meaningful intercenter comparison challenging. In this study, we propose simple and transparent statistical and clinical parameters applicable in an intercenter analysis. What is already known on this topic - the outbreak of global pandemic caused by novel coronavirus SARS-CoV-2 has strained healthcare systems all over the world. Healthcare workers faced new challenges, as organisational, structural, and personal flaws were unearthed in the process. In subsequent waves the number of hospitalisations increased together with the death number in the ICUs. As we come to terms with a new disease, numerous studies reports, analyse and assess COVID-19 treatment outcomes What this study adds - COVID-19 treatment outcomes in ICU in our facility contrast with most of the published reports. We analyse the influence of some commonly omitted under-examined factors and propose simple and applicable parameters to compare results, such as CFR and LOS, enabling a meaningful intercenter comparison. How this study might affect research, practice, or policy - inclusion of CFR and LOS in studies on COVID-19 would remove significant bias and enable more robust evaluation of therapeutic interventions and outcomes. In this study we also discuss heterogeneity of admission criteria and show how their influence on treatment outcomes.
Open AccessAnalysing COVID treatment outcomes in dedicated wards at a large university hospital in northern Poland. A result-based observational study
Introduction: Presenting outcomes of patients hospitalised for coronavirus disease (COVID-19) should be put in context and comparison with other facilities. Number of statistical parameters can be used to compare effectiveness of treatment, however varied methodology applied in studies can impede or hinder a reliable comparison. The aim of this study is to present outcomes of COVID-19 treatment in our facility using simplest parameters allowing for intercenter comparison - case fatality ratio (CFR), length of stay (LOS) and transparent patients’ characteristics, and to discuss factors affecting mortality in COVID-19. Methods: The data were collected from patients hospitalized in COVID-19 general and ICU isolation wards in the University Clinical Centre (UCC) in Gdansk, Poland, from November 2020 to June 2021, using a computer-based patient record system. The group consisted of 642 patients – 144 (39,1 %) were women and 391 (60,9 %) were men, with a median age of 69 (IQR 59-78) years. Values of LOS and CFR were calculated and analysed. Results: Overall CFR for the analysed period was 24,8 %, varying from 19,9 % in January to May 2021 to 33,8 % in November to December 2020. CFR was 18,9 % in general ward and 70,7 % in ICU. All ICU patients required intubation and mechanical ventilation, and forty-four (75,9 %) of them developed acute respiratory distress syndrome (ARDS). Average length of stay was 13,1 (± 7,1) days. Conclusion: CFR in the general ward in UCC was analogous to published outcomes, but higher in our ICU ward. It resulted from more rigorous ICU admittance criteria in UCC compared to other facilities, which corresponds with patients’ severe clinical condition and unfavourable prognosis. Heterogeneity of methods assessing initial clinical condition in different facilities makes a meaningful intercenter comparison challenging. In this study, we propose simple and transparent statistical and clinical parameters applicable in an intercenter analysis. What is already known on this topic - the outbreak of global pandemic caused by novel coronavirus SARS-CoV-2 has strained healthcare systems all over the world. Healthcare workers faced new challenges, as organisational, structural, and personal flaws were unearthed in the process. In subsequent waves the number of hospitalisations increased together with the death number in the ICUs. As we come to terms with a new disease, numerous studies reports, analyse and assess COVID-19 treatment outcomes What this study adds - COVID-19 treatment outcomes in ICU in our facility contrast with most of the published reports. We analyse the influence of some commonly omitted under-examined factors and propose simple and applicable parameters to compare results, such as CFR and LOS, enabling a meaningful intercenter comparison. How this study might affect research, practice, or policy - inclusion of CFR and LOS in studies on COVID-19 would remove significant bias and enable more robust evaluation of therapeutic interventions and outcomes. In this study we also discuss heterogeneity of admission criteria and show how their influence on treatment outcomes.
- Open Access
- 1 January 2012
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 84 (4) , 202-207
Serum Cystatin C in Relation to Fat Mass Loss After Bariatric Surgery"
Serum cystatin C concentration, generally accepted as renal function marker, is associated with cardiovascular risk and metabolic syndrome. Recent studies indicate that cystatin C increases in human obesity and that adipose tissue contributes to enhanced serum cystatin C concentration in obese subjects. The aim of the study was to assess whether a reduction in body and fat mass after bariatric surgery has any impact on serum cystatin C concentrations. Serum from 27 obese patients were tested before and 6 months after bariatric surgery. Twenty healthy subjects with normal body weight served as controls. Serum cystatin C concentrations were assayed by ELISA. Serum cystatin C concentrations were significantly higher in obese patients compared with non-obese subjects. Decrease of body and fat mass after bariatric surgery resulted in improvement of several parameters associated with cardiovascular risk and metabolic syndrome, like serum lipids, blood pressure and insulin sensitivity. Surprisingly the mean postoperative serum cystatin C concentration was not significantly different from that before surgery. Serum creatinine and GFR also remained unchanged. The results presented here suggest that serum cystatin C concentration is not tightly associated with body and fat mass loss in obese patients after bariatric surgery.
- 1 January 2012
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 84 (4) , 202-207
Open AccessSerum Cystatin C in Relation to Fat Mass Loss After Bariatric Surgery"
Serum cystatin C concentration, generally accepted as renal function marker, is associated with cardiovascular risk and metabolic syndrome. Recent studies indicate that cystatin C increases in human obesity and that adipose tissue contributes to enhanced serum cystatin C concentration in obese subjects. The aim of the study was to assess whether a reduction in body and fat mass after bariatric surgery has any impact on serum cystatin C concentrations. Serum from 27 obese patients were tested before and 6 months after bariatric surgery. Twenty healthy subjects with normal body weight served as controls. Serum cystatin C concentrations were assayed by ELISA. Serum cystatin C concentrations were significantly higher in obese patients compared with non-obese subjects. Decrease of body and fat mass after bariatric surgery resulted in improvement of several parameters associated with cardiovascular risk and metabolic syndrome, like serum lipids, blood pressure and insulin sensitivity. Surprisingly the mean postoperative serum cystatin C concentration was not significantly different from that before surgery. Serum creatinine and GFR also remained unchanged. The results presented here suggest that serum cystatin C concentration is not tightly associated with body and fat mass loss in obese patients after bariatric surgery.